Company history

Shionogi began in March 1878, when Shiono Gisaburo opened a drug wholesaling house on Osaka's Doshomachi — the street that had been the clearing house of Japan's traditional Sino-Japanese medicine trade since the Edo period. He set up on his twenty-fourth birthday, and the company still counts that day as its founding. Within a decade he walked away from the trade that gave the street its name: between 1886 and 1897 he shifted his line to Western pharmaceuticals and began dealing directly with European and American trading houses. Meiji Japan was institutionalising Western medicine, and Shiono read the turn — but taking it meant discarding the distribution network on which a Doshomachi wholesaler's living depended.

Handling Western drugs required knowing what was in them. The analytical and quality-control knowledge accumulated in the wholesaling business became the base for manufacturing: in February 1910 the firm built the Shiono Pharmaceutical Works on the Yodo River in Osaka — later the Yodogawa plant — and began making its own products, starting with quinine hydrochloride, sodium salicylate and the antacid Antachidin. A wholesaler's selling power now had a factory underneath it. In June 1919 the two halves merged into a joint-stock company, Shionogi Shoten, capitalised at ¥1.5 million, with a Tokyo branch; the First World War had cut off German supply and forced Japanese producers to make what they had imported.

In July 1943, under wartime controls, the company renamed itself Shionogi & Co., Ltd. — dropping “store” for “pharmaceutical,” a declaration in the corporate name that it was now a manufacturer. After the defeat, the third-generation head Shiono Kotaro told his executives that “from now on the world is our counterpart; unless we aim at international standards in everything we do, we cannot survive.” The company that listed after the war was a wholesaler's sales network with in-house manufacturing and raw-material research stacked vertically on top of it.

Shionogi listed on the Tokyo and Osaka exchanges in May 1949. For the next twenty years it put its capital almost entirely into domestic plant. Universal health insurance, introduced in 1961, was expanding the prescription market at double-digit rates, and supply capacity at home was a more rational investment than exports; a Taiwanese subsidiary in December 1963 was the only real venture abroad. What changed was not geography but ambition. In 1962 Shiono Kotaro told his own staff that “the history of Shionogi, the history of Japan's pharmaceutical industry — indeed the history of Japanese industry — has been a history of imitation,” and that the company had already broken with it. Original discovery and the laboratories to support it became the axis of management.

The build-out ran for four decades: the Settsu plant in 1968, Nichia Pharmaceutical (later Shionogi Pharma) in 1976, the Kanegasaki plant in Iwate in 1983, Bushu Pharmaceuticals in 1998. Shiono Motozo became president in 1999, the last of the founding family, bridging a wholesaler's culture and a research-led one. By then Shionogi was a mid-size domestic maker with drugs in central nervous system, anti-infectives, cardiovascular and lipid disorders — broad, and nowhere dominant.

The limit showed up when it tried to sell abroad itself. Shionogi USA, founded in February 2001, turned the overseas model from out-licensing toward direct sales — and ran straight into the arithmetic of the American market, where each therapeutic area needs its own specialist sales force. In the year to March 2008 the company earned ¥40.3bn of operating profit on ¥214.2bn of revenue, an 18.8% margin: comfortable at home, nowhere near enough to fund specialty sales forces across several diseases in the United States. Nikkei Sangyo Shimbun had already written in 1998 that Shionogi leaned on antibiotics in a shrinking market and lagged in internationalisation. With ¥341.9bn of shareholders' equity on the balance sheet, the question left to the next president was whether to keep spreading thin or to cut down to something that could win somewhere.

In April 2008 Teshirogi Isao, a research man, took the presidency and ended family leadership. His answer to the American arithmetic was to stop being broad: research resources were pulled back onto infectious disease, a field with a smaller market and thinner competition than the lifestyle and oncology areas his domestic rivals were chasing. In October the company paid roughly $1.5B (¥150bn) to take over the US specialty firm Sciele Pharma — buying a working sales organisation rather than spending years assembling one, precisely because entering the West on a single product looked too risky.

Then, in 2012, it declined to use what it had bought for its biggest drug. Shionogi transferred its interest in the HIV joint venture to ViiV Healthcare in exchange for a roughly 10% shareholding and a royalty in the high teens on dolutegravir, the integrase inhibitor its own labs had discovered, letting GSK's organisation sell it worldwide. The effect on the accounts was extreme. Operating profit rose from ¥32.0bn in the year to March 2009 to ¥63.5bn in 2014 and ¥115.2bn in 2018, while revenue over the same span moved only from ¥227.5bn to ¥344.6bn — profit compounding at more than twice the pace of sales, because the selling costs sat on someone else's books. In the year to March 2019, revenue of ¥363.7bn produced ¥138.5bn of operating profit, a 38.1% margin; interest-bearing debt of ¥115.0bn a decade earlier had been reduced to a single ¥0.9bn bond, and equity had nearly doubled to ¥667.3bn.

The organisation was rebuilt to match. A single drug-discovery centre opened at Settsu in 2011, physically consolidating research that had been scattered across therapeutic areas. Consumer health was carved out into Shionogi Healthcare in 2016; manufacturing was gathered into Shionogi Pharma from 2018; Sciele's successor, Shionogi Inc., became the American base. Research, manufacturing and sales each stood as a separate body around one franchise — a light structure whose logic was that Shionogi would discover drugs and let others carry them to market.

When COVID-19 arrived, Shionogi did something its balance sheet allowed and its caution normally would not: it began building manufacturing capacity for an antiviral before the clinical trials that would decide whether the drug worked. Teshirogi admitted as much in October 2020. By the time approval came the company had a line running for ten million courses a year. In parallel it opened joint ventures with Ping An in Hong Kong and China in 2020, its first serious push into the Chinese market.

On 22 November 2022, Zocova (ensitelvir) was approved under Japan's new emergency approval framework — the first domestic oral COVID-19 treatment, and the first use of the framework itself, granted without waiting for the completed Phase 3 result. A government purchase of $761.2M (¥100bn) landed in the same quarter, and shipments to wholesalers began the day after approval because the factory was already there. For the year to March 2023 revenue reached ¥426.7bn (up 27.3%), operating profit ¥149.0bn (up 35.1%) and net profit ¥185.0bn — all records, and the first time revenue had passed the ¥420.2bn set in 2002, twenty years earlier. R&D spending crossed ¥100bn.

The vindication was narrower than the numbers suggest. Infectious-disease specialists did not move Zocova up their prescribing order, and a teratogenic drug reached 23 pregnant women — the cost of a framework that trades confirmed efficacy for speed of supply. Teshirogi, who added the chairmanship to the presidency in June 2022, put it more modestly: the company had finally reached a structure in which it could aim at growing sales, not only margins. In January 2026 Shionogi raised its ViiV holding to 21.7% of the votes, making it an equity-method affiliate — after fourteen years as a 10% shareholder in the business that pays for everything else.